非酒精性脂肪性肝病血清学检测进展  

Progress in serum markers for non-alcoholic fatty liver disease

作　　者：王晓晓[1] 李晓鹤 刘峰[1] 魏来[1] Wang Xiaoxiao;Li Xiaohe;Liu Feng;Wei Lai(Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases,Peking University Hepatology Institute,Peking University People's Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院,北京大学肝病研究所,丙型肝炎和肝病免疫治疗北京市重点实验室,100044

出　　处：《中华检验医学杂志》2019年第3期165-169,共5页Chinese Journal of Laboratory Medicine

摘　　要：非酒精性脂肪性肝病(NAFLD)的流行率逐年升高。NAFLD的病理变化从单纯性肝脂肪变进展为脂肪性肝炎,并可最终进展至中晚期肝纤维化,因此准确诊断和鉴别非酒精性脂肪性肝炎(NASH)和纤维化对NAFLD的治疗和管理是必要的。传统的金标准——肝活检是一种有创操作,不适合大规模人群的筛查和监管。目前基于血清学检测的无创NAFLD诊断标志物将是NAFLD诊断研究的新方向。本文就近来的实验室检测、临床参数、基因组和代谢组学相关NAFLD无创血清学标志物进行综述,以期为后续临床研究和应用提供参考。The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing gradually.The pathological changes of NAFLD can progress from simple hepatic steatosis to steatohepatitis,and to advanced liver fibrosis ultimately.Accurate diagnosis and identification of nonalcoholic steatohepatitis (NASH) and fibrosis patients are necessary for the treatment and management of NAFLD.The traditional gold standard--liver biopsy is an invasive procedure that is not suitable for clinical practice and clinical trials.Some non-invasive markers for NAFLD based on serological testing will be a new direction for the diagnosis of NAFLD.This article reviews the laboratory tests,clinical parameters,genomic and metabolomics-related NAFLD non-invasive serological markers.

关 键 词：非酒精性脂肪性肝病 血清学试验 临床实验室技术 

分 类 号：R575.5[医药卫生—消化系统]